A committee to be formed to suggest measures for ensuring the safety of healthcare professionals
The emergence of new infections in India is a growing concern
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
The robotic surgery program has continually pushed the boundaries of medical technology
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Subscribe To Our Newsletter & Stay Updated